Literature DB >> 15033791

CD4+ lymphocyte increases in HIV patients during potent antiretroviral therapy are dependent on inhibition of CD8+ cell apoptosis.

Sandro Grelli1, Gabriella D'Ettore, Filippo Lauria, Francesca Montella, Loide Di Traglia, Cartesio D'Agostini, Miriam Lichtner, Vincenzo Vullo, Cartesio Favalli, Stefano Vella, Beatrice Macchi, Antonio Mastino.   

Abstract

Although suppression of apoptosis contributes to immune-reconstitution during potent antiretroviral therapy, its relationship with the majors indicators of response to therapy, that is, changes in CD4(+) cell counts and in viral loads (VL), is still debated. We extended our previous study by collecting data on the relationships among apoptosis and immunological and virological parameters during a long-term follow-up of HIV patients with an overall positive response to potent antiretroviral therapy. We report results from 15 patients who completed two years of therapy. In a smaller group of patients, we focused our attention on investigating the specific contribution of the CD8(+) subset in the overall changes in lymphocyte apoptosis, which occur concomitantly with the response to the therapy. Our data, while again confirming that inhibition of PBMC apoptosis is a phenomenon strictly related to a positive response to potent antiretroviral therapy, suggest that CD4(+) cell rescue is not directly dependent on inhibition of CD4(+) cell apoptosis but rather on that of the CD8(+) subset.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15033791     DOI: 10.1196/annals.1299.104

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  1 in total

1.  The CD8⁺ memory stem T cell (T(SCM)) subset is associated with improved prognosis in chronic HIV-1 infection.

Authors:  Susan P Ribeiro; Jeffrey M Milush; Edecio Cunha-Neto; Esper G Kallas; Jorge Kalil; Ma Somsouk; Peter W Hunt; Steven G Deeks; Douglas F Nixon; Devi SenGupta
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.